Results 41 to 50 of about 431,159 (301)

Carbapenem-Resistant Gram-Negative Bacterial Infections in Children

open access: yesAntimicrobial Agents and Chemotherapy, 2020
Carbapenem-resistant organisms (CRO) are a major global public health threat. Enterobacterales hydrolyze almost all β-lactams through carbapenemase production. Infections caused by CRO are challenging to treat due to the limited number of antimicrobial options. This leads to significant morbidity and mortality. Over
Aguilera-Alonso, David   +4 more
openaire   +4 more sources

Epidemiology of antibiotic resistance in culture-positive hospitalized patients in selected hospitals in Khartoum, Sudan [PDF]

open access: yes, 2019
Objective: To study the prevelence of antibiotic resistance and the prevalent bacterial isolates in hospitalized patients in Khartoum hospitals. Materials & Methods: A cross-sectional prevalence study was carried out during the period of April ...
Abdalrahman, Ihab B   +3 more
core   +4 more sources

Bacterial Outer Membrane Vesicles as a Versatile Tool in Vaccine Research and the Fight against Antimicrobial Resistance

open access: yesmBio, 2021
Gram-negative bacteria include a number of pathogens that cause disease in humans and animals. Although antibiotics are still effective in treating a considerable range of infections caused by Gram-negative bacteria, the alarming increase of ...
Zhuang Zhu   +3 more
doaj   +1 more source

Bacterial infections in patients with liver cirrhosis and ascites [PDF]

open access: yesSrpski Arhiv za Celokupno Lekarstvo, 2014
Introduction. Bacterial infections are common complications and the cause of death in patients with cirrhosis and ascites. There is no standard method for a rapid and low-cost diagnosis, and its prognosis is poor. Objective.
Marković-Živković Bojana   +6 more
doaj   +1 more source

Antibacterial and anti-quorum sensing activities of selected italian honeys against antibiotic-resistant pathogens [PDF]

open access: yes, 2015
Three nectar honeys (eucalyptus, thyme and forest) and two honeydew honeys (fir and Metcalfa) from Italy were tested for their antibacterial activity against pathogens commonly associated with wound and burn infections, including methicillin-resistant ...
Fidaleo, Marco   +2 more
core   +1 more source

Infection-related hemolysis and susceptibility to Gram-negative bacterial co-infection [PDF]

open access: yesFrontiers in Microbiology, 2015
Increased susceptibility to co-infection with enteric Gram-negative bacteria, particularly non-typhoidal Salmonella, is reported in malaria and Oroya fever (Bartonella bacilliformis infection), and can lead to increased mortality. Accumulating epidemiological evidence indicates a causal association with risk of bacterial co-infection, rather than just ...
Cunnington, A, Orf, K
openaire   +4 more sources

Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA) [PDF]

open access: yes, 2016
Intra-abdominal infections (IAI) are an important cause of morbidity and are frequently associated with poor prognosis, particularly in high-risk patients.
A   +173 more
core   +4 more sources

Incidence and outcomes of multidrug-resistant gram-negative bacteria infections in intensive care unit from Nepal- a prospective cohort study

open access: yesAntimicrobial Resistance and Infection Control, 2018
Background Infections caused by multi-drug resistant gram-negative bacterial infections are the principle threats to the critically ill patients of intensive care units.
Shraddha Siwakoti   +5 more
doaj   +1 more source

Measures to eradicate multidrug-resistant organism outbreaks: How much does it cost? [PDF]

open access: yes, 2015
This study aimed to assess the economic burden of infection control measures that succeeded in eradicating multidrug-resistant organisms (MDROs) in emerging epidemic contexts in hospital settings.
Birgand, GJC   +6 more
core   +1 more source

Imipenem/Cilastatin/Relebactam: A Review in Gram-Negative Bacterial Infections [PDF]

open access: yesDrugs, 2021
Imipenem/cilastatin/relebactam (Recarbrio™) is an intravenously administered combination of the carbapenem imipenem, the renal dehydropeptidase-I inhibitor cilastatin, and the novel β-lactamase inhibitor relebactam. Relebactam is a potent inhibitor of class A and class C β-lactamases, conferring imipenem activity against many imipenem-nonsusceptible ...
openaire   +3 more sources

Home - About - Disclaimer - Privacy